Skip to main content
Premium Trial:

Request an Annual Quote

Alere Gets FDA Clearance for Molecular Flu A/B Test

NEW YORK (GenomeWeb) — Alere said today that it has received US Food and Drug Administration Clearance for the Alere i Influenza A&B test.

According to Alere, the new assay is the only molecular test to detect and differentiate influenza A and B virus in less than 15 minutes. The test uses Alere's proprietary "Molecular. In Minutes" (MIM) isothermal nucleic acid amplification technology, which unlike PCR does not require thermal cycling or DNA purification, thus reducing time to result.

Alere established the assay's clinical performance in a multi-center, prospective study conducted on 585 nasal swab specimens collected at eight US trial sites during the 2012-2013 flu season.

Alere, based in Waltham, Mass., launched the i Influenza A&B test earlier this year in Europe. The company has also completed clinical trials for CLIA waiver of the test, and expects to submit a CLIA waiver filing to the FDA in the third quarter.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.